Project Grant R01CA300202
Award Date
6/1/25
Completion Date
5/31/30
Dollars Obligated
$695K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $600,079 to The Washington University to develop and evaluate a novel combination radiotherapy approach for treating relapsed and refractory neuroblastoma, a challenging pediatric cancer. The research aims to combine high linear energy transfer (high-LET) therapies targeting two key neuroblastoma biomarkers, norepinephrine transporter (NET) and somatostatin receptor 2 (SSTR2), to...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Trustees of the University of Pennsylvania, Clinical Practices of the University of Pennsylvania, totaling $552,763 from January 1, 2025 to December 31, 2029. The grant aims to assess the therapeutic potential of newly developed KAT6 inhibitors (KAT6i) as monotherapy and in combination with targeted therapy drugs in preclinical models of high-grade serous ovarian cancer (HGSOC) and...
This $627,573 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to optimize radioligand therapy dosimetry and kidney biomarkers for alpha-emitter radiotherapy in neuroendocrine tumors. The key products and services to be delivered include: Developing a detailed understanding of the role of superoxide dismutation in tubular DNA repair following alpha-emitter radiotherapy Identifying optimal dosing regimens of the [212Pb]Pb-VMT-A-NET...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel dual-targeting ligand called BG-P-TAT (NP855) for the treatment of high-risk neuroblastoma. Nanopharmaceuticals LLC, the awardee, is evaluating the efficacy and safety of this ligand, which combines a plasma membrane integrin αvβ3 antagonist and a norepinephrine transporter (NET) targeting compound. The $792,367 award will fund studies to confirm the in...
The National Cancer Institute (NCI) awarded a $205,621 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Alabama at Birmingham (UAB) to develop a novel nanobody framework with reduced kidney retention for use in targeted radiotherapy. The key products and services to be delivered under this 2-year grant, which began on December 9, 2024, include: Generating a new nanobody framework with over 90% reduction in kidney retention compared to existing immunization-derived...
The National Cancer Institute (NCI) awarded a $400,000 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Expression Therapeutics, Inc. to advance the development of a promising lead candidate for an allogeneic cell and gene therapy for neuroendocrine tumors (NETs). The goal is to move this ADEPT-STAR-NET candidate therapy towards clinical testing. NETs are a rare type of cancer that has been increasing in incidence over the past 30 years. Current treatment options are limited, with no...
The National Cancer Institute (NCI) awarded Oncotab, Inc. a $400,000 Project Grant (CFDA 93.395 - Cancer Treatment Research) to develop an optimized targeted radiotherapy for pancreatic ductal adenocarcinoma (PDAC). The goal is to overcome the challenges of delivering effective treatments to PDAC tumors, which have a very low 5-year survival rate of less than 9%. The project will involve a structured design of experiments to evaluate the use of a humanized tumor-associated MUC1 (TMUC1)...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Trustees of the University of Pennsylvania (Clinical Practices of the University of Pennsylvania) totals $530,697 over the period of August 29, 2024 to July 31, 2029. The grant supports research to investigate the use of protein arginine methyltransferase (PRMT) inhibitors as potential new therapeutic approaches for treating high-grade serous ovarian cancer and triple-negative breast...
The National Cancer Institute (NCI) awarded a $644,034 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a nanoparticle-based drug delivery platform that uses radiation to control the release of chemotherapy payloads within irradiated tumor tissue. The project aims to expand the therapeutic window of chemoradiation by improving local disease control while mitigating...
The National Cancer Institute (NCI) awarded a $200,000 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The grant, awarded on September 15, 2023, supports research to develop novel therapeutic approaches to remediate radiotherapy-induced bone necrosis in oropharyngeal cancer patients, particularly among African-American populations who...